H&K lands DeSalva to head global healthcare

Share this article:
Hill & Knowlton named GCI Group's AnnaMaria DeSalva to head its worldwide healthcare practice.

DeSalva, who was previously worldwide managing director of the healthcare practice at GCI Group, the PR arm of WPP's Grey Global Group, becomes director, worldwide healthcare practice at Hill & Knowlton.

Before joining GCI group, DeSalva spent six years at Bristol-Myers Squibb (BMS), where she coordinated marketing and government relations teams in Europe to drive reimbursement and adoption of anti-cancer treatments, developed corporate affairs strategy for Latin American and Asia Pacific markets, and led strategic planning and health programs at the BMS Foundation.

DeSalva's is the latest in a string of recent high-level moves at the healthcare practices of top PR agencies. She replaces Paul Oestreicher, who left to head the New York office and healthcare practice of Zeno Group. Oestreicher, in turn, replaced Charlotte Wray, who left Zeno Group to launch Mosaic, a new healthcare firm backed by Omnicom's Brodeur Group.

GCI Group has not named a replacement for DeSalva.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...